Matthias Kometer
Neuroscientist and Clinical Researcher
Papers
Trials
Key Impact
Notable for pioneering human neuroimaging and psychopharmacological research that has elucidated how serotonergic psychedelics alter self-processing, affect and social cognition, and for translating these findings toward psychiatric applications.
Background & Research
Matthias Kometer is a neuroscientist and clinical researcher known for a body of work that combines psychopharmacology, neuroimaging (fMRI/EEG) and cognitive neuroscience to study the effects of serotonergic psychedelics in humans. Working within clinical research groups that include the Vollenweider lab at the University of Zurich, Kometer has contributed key empirical studies and reviews that map the pharmacological, neural and psychological mechanisms of compounds such as psilocybin, DMT/ayahuasca-inspired formulations and classical hallucinogens. His research spans acute neural responses (including P300 and other event-related potentials), changes in default mode network connectivity, and behavioural outcomes such as empathy, moral decision-making and self–other processing.